Clinical trial · Observational
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
An Observational Study of Novel Survival Prediction Algorithm as Clinical Decision Support for Patients With Non-Small-Cell Lung Cancer (NSCLC) Spinal Metastasis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn whether our own made predictive algorithm can be used as a clinical practical decision support for patients with NSCLC spinal metastasis. The scoring system consists of the use of EGFR-TKI, KPS, Age, SCC, CA125 and smoking history. By predicting survival doctors could determine which patients are suitable for palliative therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small-Cell Lung Cancer Metastatic | — | UNRESOLVED | — |
| Spinal Metastases | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- Low risk
- description
- For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
- label
- Intermediate risk
- description
- For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
- label
- High risk
- description
- For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
Primary outcomes (1)
- measure
- Survival
- timeFrame
- Every 6 months from date of diagnosis of NSCLC spinal metastasis until the date of death from any cause, assessed up to 3 years
- description
- Accuracy and sensitivity of novel survival prediction algorithm derived from differences between the predicted and actual survival of NSCLC spinal metastasis patients from 3 different risk groups.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis by biopsy: Non-small-cell lung cancer, including non-squamous carcinoma and squamous cell carcinoma. * Diagnosis through both nucleotide bone scan and MRI or PET-CT: spinal metastasis. * Age 18-75 years. * Have been or is about to be treated according to NCCN panel recommendation. Exclusion Criteria: * Diagnosis by biopsy: other tumors. * Irregular follow-up and lost follow-up * Withdraw from the study for any reason
References
Publications (1)
- DERIVEDZang S, He Q, Bao Q, Shen Y, Zhang W. Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis. Int J Clin Oncol. 2019 Sep;24(9):1049-1060. doi: 10.1007/s10147-019-01452-8. Epub 2019 Apr 26. PMID 31028506